Scientists Name Genzyme a Top Employer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

The survey, which was commissioned by Science magazine and the American Association for the Advancement of Science (AAAS), identified the top 20 companies with the best reputations as employers. More than 2,300 Science readers and other industry representatives participated in the survey. Genzyme earned the most votes in the following categories: innovation, important and quality research, and loyal employees.

“We attempt to create an atmosphere in which the passion of our scientists for understanding and treating disease has the greatest chance of translating into innovative therapies for unmet medical needs,” said Alan Smith, Ph.D., senior vice president of research and chief scientific officer at Genzyme. “I am proud that the respect we feel for the dedication and talent of our staff is matched by the scientists who participated in the survey in judging what we do at Genzyme.”

About the Survey

Science’s annual survey of Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries. Respondents to the web-based survey are asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change, and a research-driven environment. More than 70 percent of survey participants came from North America, 15 percent came from Europe, and nearly 10 percent came from the Pacific Rim; 85 percent worked in private industry.

Survey responses were analyzed by The Brighton Consulting Group, which used a mathematical process to assign a unique score to rate the companies’ employer reputation. Each company received a ranking, for example, on the basis of whether it treats its employees with respect, whether its work-culture values align with employees’ personal values, and other factors.

To read the full survey, please visit:

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme is a leader in the effort to develop and apply the most advanced scientific technologies. Scientists working at Genzyme have developed novel treatments that are helping patients in more than 90 countries worldwide. The company is bringing new and next-generation therapies to patients with genetic diseases, kidney disease, cancer, osteoarthritis, as well as transplant and immune diseases. The company is also a leader in the development of diagnostic and genetic tests.

For information about careers at Genzyme, please visit:

Genzyme’s press releases and other company information are available at and by calling Genzyme’s investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact:
Sarah Connors, 617-768-6438
Investor Contact:
Emily Merchant

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.